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Abstract
Glioblastoma (GBM) is the most common and aggressive primary CNS malignancy with a median
survival of 15 months. The average incidence rate (IR) of GBM is 3.19/100,000 population and
the median age of diagnosis is 64 years. Incidence is higher in men and individuals of white race
and non-Hispanic ethnicity. Many genetic and environmental factors have been studied in GBM
but the majority are sporadic and no risk factor accounting for a large proportion of GBMs has
been identified. However, several favorable clinical prognostic factors are identified including,
younger age at diagnosis, cerebellar location, high performance status and maximal tumor
resection. GBMs comprise of primary and secondary subtypes which evolve through different
genetic pathways, affect patients at different ages and have differences in outcomes. We report the
current epidemiology of GBM with new data from the Central Brain Tumor Registry of the United
States (CBTRUS) 2006–2010 as well as demonstrate and discuss trends in incidence and survival.
We also provide a concise review on molecular markers in GBM that have helped distinguish
biologically similar subtypes of GBM and have prognostic and predictive value.
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GBM is the most aggressive diffuse glioma of astrocytic lineage and corresponds to grade
IV based on WHO Classification (1). GBM is the most common brain and CNS malignancy,
accounting for 45.2% of malignant primary brain and CNS tumors, 54% of all gliomas, and
16% of all primary brain and CNS tumors (2). GBM remains an incurable disease with a
median survival of 15 months (3, 4). Treatment is complex and initially consists of
maximal-safe surgical resection followed by radiation therapy (RT) with concurrent
temozolomide (TMZ) chemotherapy followed by six cycles of maintenance TMZ (5).
GBMs comprise of primary and secondary subtypes which evolve through different genetic
pathways, affect patients at different ages and have differences in outcomes (6). Primary (de
novo) GBMs account for 80% of GBMs and occur in older patients (mean age 62 years).
Secondary GBMs develop from lower-grade astrocytoma or oligodendrogliomas and occur
in younger patients (mean age 45 years) (6–9). The WHO recently added a rare subtype of
GBM termed ‘with oligodendroglioma component’ (GBM-O) defined as GBM having areas
that resemble anaplastic oligodendroglioma with hallmark features of GBM, necrosis with
or without microvascular proliferation (1).
Epidemiology
Incidence and risk factors
Based on the 2013 CBTRUS report, the average annual age-adjusted incidence rate (IR) of
GBM is 3.19/100,000 population (2). This is the highest IR among brain and CNS tumors
with malignant behavior followed by diffuse astrocytoma grade 2 (0.56/100,000), and
malignant glioma not otherwise specified (0.46/100,000) (2). Incidence is highest in the
northeast and lowest in the south-central region of US (Figure 1), however these differences
could reflect differences in cancer reporting by region (2). Many genetic and environmental
factors have been studied in GBM but no risk factor that accounts for a large proportion of
GBM has been identified and like many cancers are sporadic (10).
Age—GBM is primarily diagnosed at older ages with the median age of diagnosis of 64
years (2, 11). It is uncommon in children accounting only approximately 3% of all brain and
CNS tumors reported among 0–19 year olds (2). The incidence continues to rise with
increasing age, peaks at 75–84 years of age and drops after 85 years (Figure 2) (2). With a
growing and aging US population, the number of cases is expected to increase (12).
Gender—Differences in incidence and death rates for specific cancers based on race and
ethnic groups as well as gender, suggest potential identifiable biologic and environment
based variables (13, 14). A higher incidence of GBM has been reported in men as compared
to women (Figure 2) (2, 11, 15–17). The IR of GBM is 1.6 times higher in males as
compared to females [3.97 versus 2.53] (2) with a higher frequency of primary GBMs men
(male to female ratio, 1:33) and secondary GBMs in women (male to female ratio, 0:65) (7).
Race/Ethnicity—Whites have the highest incidence rates for GBM, followed by blacks,
Asian/Pacific Islanders (API) and American Indian/Alaska Native (AI/ANs) (Figure 3A) (2).
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From 2006 to 2010, whites had two times higher IR as compared to blacks [3.45 versus
1.67] (Figure 3A) and non-Hispanics had higher IR as compared to Hispanics [3.26 versus
2.45] (Figure 3B) (2, 11).
Site—GBMs are more commonly located in the supratentorial region (frontal, temporal,
parietal and occipital lobes), are rarely seen in the cerebellum and are very rare in the spinal
cord (18, 19). A SEER population-based study (1973 to 2009) did find a difference in the
behavior of GBM at these two locations (19). When compared to supratentorial location,
cerebellar GBMs occurred in younger patients, occurred less commonly in whites and were
smaller in size (19–21). Cerebellar GBM occurs rarely in adults, accounting for 0.4–3.4% of
all GBMs (21). Patients with cerebellar GBM are significantly younger than those with
supratentorial tumors (median age of 50–56 years in contrast to 62–64 years for patients
with supratentorial GBM) (21). A population based study of the Los Angeles County
reported that, GBM had the highest incidence for frontal lobe tumors and for tumors that
involved two or more lobes (overlapping tumors), followed by tumors in the temporal and
parietal lobes (11). The male to female ratio was elevated for each brain sub-site except the
posterior fossa; occipital lobe amongst these sites had the greatest ratio (11).
Summary of Risk—Factors associated with GBM risk are prior therapeutic radiation,
decreased susceptibility to allergy, immune factors and immune genes, as well as some
single nucleotide polymorphisms (SNPs) detected by genome wide association studies
(GWAS) (22–25). A lower risk of gliomas has been associated with allergies or atopic
diseases (e.g. asthma, eczema, psoriasis) and the protective effect does not vary by major
histologic subtypes of glioma or by histologic grade (26–28). Additionally, short term (< 10
years) use of anti-inflammatory medications is associated with a protective effect against
GBM, especially among individuals with no history of asthma or allergies (29). GWAS have
detected increased risk of high grade glioma with inherited variation in a region containing
cyclin-dependent kinase inhibitor 2B (CDKN2B) on Chromosome 9p21 and in two SNPs in
regulator of telomere elongation helicase 1(RTEL1) (25). Other factors associated with
GBM risk are high socio-economic status (SES) and taller height (11, 30). The higher SES
groups were up to 70% more likely to be diagnosed with GBM in the frontal lobes and they
had higher IR for all tumor sites, except for posterior fossa tumors (11).
There is no substantial evidence of GBM association with life-style characteristics such as
cigarette smoking, alcohol consumption, use of drugs of any kind or dietary exposure to N-
nitroso compounds (cured or smoked meat or fish) (31). Inconsistent and non-definitive
results have been published regarding the risk of glioma with use of mobile phones (32–37).
Survival and Prognostic Factors
GBM has a poor prognosis with quite low relative survival estimates, only a few patients
reaching long-term survival status of 2.5 years and less than 5% of patients survive 5 years
post diagnosis (Figure 4A) (2, 38). The relative survival for the first year after diagnosis is
35% and it falls in the second year post diagnosis (13.7%) and thereafter (2) (Figure 4A). A
population based study found that the first quarter of the second year (5th quarter) post-
diagnosis is considered to be the peak incidence of mortality and the risk of death decreases
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to half of its rate at 2.5 years (38). Despite these unfavorable survival and mortality
estimates, there exists reassuring data for conditional probability of survival in GBM
(likelihood of surviving into the future based on previous survival) (39). Patients surviving
past 2 years from diagnosis have a relatively favorable conditional probability of survival
into the future compared to newly diagnosed patients (39, 40).
GBM is an aggressive neoplasm which has a median survival of 3 months if untreated (41,
42). Combined modality therapy with surgery, RT and chemotherapy has significantly
improved survival of GBM patients. Surgical intervention has decompressive and
cytoreductive effects and there is increasing evidence of a significant survival advantage
with complete resection (43, 44). Tumor fluorescence derived from 5-aminolevulinic acid
enables more complete resections of contrast-enhancing tumor, leading to improved
progression-free survival in patients with malignant gliomas (45).
In 2004 the European Organization for Research and Treatment of Cancer (EORTC) group
and National Cancer Institute of Canada Clinical Trials Group (NCIC) presented a phase III
study demonstrating a significant improvement in 2 year overall survival from 10.4% with
post-operative radiotherapy alone to 26.5% with post-operative combined radiotherapy plus
TMZ and an improvement in median overall survival (OS) from 12.1 to 14.6 months (5).
These results also translated into a survival benefit in a population-based cohort after
introduction of TMZ in 2005 (3). Additionally, a survival benefit was seen in each recursive
partitioning analysis (RPA) class with combined modality therapy as compared to RT alone
(46). The RPA classification is based on pre-therapeutic prognostic factors that have a more
powerful impact on survival than any adjuvant treatment (47). It helps determine a particular
category of patients who will benefit most from newer therapeutic approaches. The RTOG
RPA classification is based on age, Karnofsky Performance Status (KPS) and neurologic
function; classes III and IV include anaplastic astrocytomas as well as GBM. The EORTC
RPA classification is based on age, WHO performance status and neurologic function
determined by mini mental status exam; classes III and IV include only GBM patients (46).
The overall median survival and 2 year survival was highly statistically different after
combined modality treatment (RT + TMZ) among the three prognostic EORTC RPA classes
(class III, IV, V) (46). The survival benefit of combined treatment as compared to RT alone
was highest in RPA class III, advantage in class IV remained highly significant and there
was small difference of borderline significance in class V(46).
Several variables affect the prognosis of patients with GBM, including age, preoperative
performance status, tumor location, preoperative imaging characteristics of the tumor and
extent of resection (7, 44, 47).
Site—The prognosis of cerebellar GBMs with respect to their supratentorial counterparts
has been unclear (19–21, 48–50). However, age associated differences in survival are
apparent at a younger age in cerebellar as compared to supratentorial GBMs (40 years
versus 60 years) (19–21). Among supratentorial GBMs, frontal lobe tumors have better
survival as compared to other sites (51, 52).
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Gender—The relative survival in both men and women is the highest at 1 year (36.7% and
32.8% respectively), it declines steeply in the second year (13.7% in both genders) and
gradually thereafter, with a very low 5 year survival rate (4.7% and 4.6% respectively)
(Figure 4B) (2). Men have a significant survival advantage than women in the first year
post-diagnosis but the difference is not significant thereafter (2).
Race—Population-based studies do not demonstrate a race based disparity in GBM survival
(53–57). No significant differences in GBM survival have been observed among whites and
blacks; however, Asian Pacific Islanders have a significantly better survival rates than both
whites and blacks at all time points (Figure 4C) (2). In our recent population-based study,
we studied interrelations between race, surgery received, and survival of GBM patients who
were not treated with initial RT (57). We did not find race-based differences in outcomes
among these GBM patients receiving different surgical interventions (57). The limited
influence of therapy on GBM may be responsible in part for this result (55). There is also a
possibility that biologic factors influencing GBM outcomes could be similar across races
(57).
Age—Age of 50 years has been identified as an appropriate cut-off age for the clinical
subdivision of patients with GBM into prognostically relevant subsets (7). In multivariate
analysis of overall survival risk factors increasing age is associated with shortened survival
(Figure 5) (2). Patients aged 70–74 and those >75 have a significantly higher risk of death
than those 65–69 (58). Poorer survival in the older age group has been attributed to co-
morbidities as well as decreased ability to withstand neurological insults caused by the
tumor itself, surgery and/or adjuvant therapy (47, 59, 60). Additionally, aggressive tumors in
older patients have been attributed to resistance genes and tumors with different molecular
profiles (61–63).
Miscellaneous Factors—Various other factors including socioeconomic status (SES)
and marital status could be associated with GBM survival differences. Marital status had a
beneficial effect on survival in a SEER based population study, where unmarried patients
with supratentorial GBM presented with larger tumors, were less likely to undergo both
surgical resection and postoperative RT, and had a shorter survival after diagnosis when
compared with married patients (64).
Effects of SES on survival have been examined by studying the primary payer for care
(Medicare, Medicaid, self-pay, or private insurance) as predictor of in-hospital mortality
(65). Compared with Medicare patients, Medicaid patients had higher mortality (58). For
GBM patients with dual eligibility in Medicare and Medicaid were much less likely to report
radiation claims than those with Medicare alone (58). Higher chemotherapy claims were
reported in patients with a median annual income >35,000 than those with <25,000 (58).
Those who reported radiation or chemotherapy claims had a significantly lower risk for
death than those who did not (58).
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In our recent SEER population-based study we did not find an obvious racial difference in
receipt of RT for GBM patients (57). However, another SEER population-based study
investigating the influence of regional health system resources on the surgical management
of GBM and receipt of post-operative RT, found that younger, married patients in health
service areas (HSAs) with higher median incomes were significantly more likely to receive
both gross total resection and post-operative RT (66). For every $10,000 increase in the
median income of a HSA, a patient’s likelihood of receiving gross resection increased by 7
% and post-operative RT receipt by 6.3 % (66). Their findings indicated that it may not be
the density of individual radiation oncologists, but rather the prevalence of radiation
oncology centers that influences post-operative RT receipt, suggesting a dominant role of
hospital-level infrastructure over individual providers for addressing disparities in GBM
management (66). It is possible that the large variations in treatment of GBM may be related
less to access to neuro-oncology services, but a larger apprehension of physicians to attempt
aggressive surgery and RT for patients with less favorable prognosis (66).
A significant percentage of GBM patients (27.3%) do not receive RT in the initial round of
therapy and majority of these are elderly patients (65 years and older) (57, 67). Similar
trends are seen in other SEER based population studies for breast and lung cancer where
lower rates of RT with increased age were observed (68, 69). Under-use of RT in a large
number of elderly GBM patients could be attributed increased risk of cognitive side-effects
associated with RT (67, 70). However, recent data does show benefit of RT in the elderly
population (71).
Prognostic Molecular Markers in GBM
Various molecular markers are associated with varying grades of glioma (Figure 6). All
GBMs are WHO grade IV but exhibit significant genetic heterogeneity and tumor subtypes
with genetic alterations exist within this larger homogeneous histologic category that carry
prognostic significance (6, 72). Various prognostic markers have been identified in GBM,
including methylation status of the gene promoter for O6-methylguanine-DNA
methyltransferase (MGMT), isocitrate dehydrogenase enzyme 1/2 (IDH1/2) mutation,
epidermal growth factor receptor (EGFR) overexpression and amplification, glioma-CpG
island methylator phenotype (G-CIMP), tumor protein (TP53) mutation and genetic losses
of chromosomes.
Primary GBMs show EGFR overexpression, phosphatase and tensin homolog gene (PTEN)
mutations, loss of heterozygosity (LOH) 10q, p16 deletions, less frequently mouse double-
minute 2 (MDM2) amplification, high frequency of telomerase reverse transcriptase
(hTERT) promoter mutations and absence of IDH1 mutation (9, 73). The hallmark of
secondary GBMs is TP53, alpha thalassemia/mental retardation syndrome X-linked (ATRX)
and IDH1 mutations; additionally, they show LOH 10q (7–9). GBM-O occurs in younger
patients and often contains TP53 mutations, IDH1 mutation and lack of EGFR amplification
(6, 74). They have been reported to have longer survival as compared to other GBMs, have a
lower frequency of PTEN deletions, and genetic heterogeneity (75–79).
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There is a complex interaction between age and genetic alterations that result in variation of
clinical outcomes in different age groups (72, 80, 81). GBM patients age < 50 years have
molecularly and clinically distinct disease and age 40 years appears to be a more appropriate
cut-off point for their further prognostic subdivision (82). Patient age < 40 years is strongly
associated with a favorable prognosis while ≥ 40 years shows markers associated with
shorter survival (wild type IDH1/2, EGFR amplification, loss of 9p, loss of 10q, and gain of
chromosome 19) (82).
MGMT Status
TMZ is an alkylating agent that functions by transferring alkyl groups to guanine bases
causing DNA damage and cellular death. Failure to repair alkylation results in apoptosis.
MGMT is a DNA repair protein that removes alkyl groups from the O6 position of guanine
in DNA, making cells resistant to the alkylating agent TMZ (83, 84). Methylation causes
MGMT silencing that interferes with DNA repair and increases TMZ sensitivity while an
unmethylated promoter for MGMT, results in active gene expression and high levels of the
repair enzyme that results in chemotherapy resistance (85, 86).
The MGMT promoter is methylated in approximately 50% of newly diagnosed GBMs (87–
89). MGMT methylation is associated with IDH1/2 mutant tumors due to which it is more
common in secondary as compared to primary GBM (75% versus 36% respectively) (86, 90,
91). MGMT promoter methylation has prognostic and predictive significance in patients
with GBM with better overall survival (OS) irrespective of treatment choices (84, 92, 93).
Additionally, it is associated with better response to TMZ as well as RT and improves
progression free survival (PFS) and OS with combined treatment approach (TMZ + RT)
than either treatment modality alone (77, 84, 92, 94, 95).
IDH Mutation
IDH1/2 mutations are far more common in grades II and III astrocytomas and
oligodendrogliomas compared to GBMs and over 90 % of the mutations involve IDH1(74,
96–99). The effects of IDH1/2 mutations on gliomagenesis are greater than inhibition of
their wild-type counterparts, and more likely represent a true gain-of-function genetic
change (100). IDH1-R132H point mutated enzyme (mutation in IDH1 at R132) prefers
binding to alpha-ketoglutarate and reduces it to D-2-hydroxyglutarate (100). The levels of
this oncometabolite are 10–100-fold higher in mutant gliomas than their wild-type
counterparts (100).
IDH mutations tend to occur in younger adults (20–60-year range) (101–104). The relative
frequency of IDH1 tumors rises sharply in the third decade of life and decreases in the fifth
decade (105). IDH1 mutated high grade gliomas arise by transformation from lower-grade
gliomas and have distinguishing radiographic, histologic and transcriptional features (frontal
location and lesser extent of contrast enhancement and necrosis) that are consistent with a
less aggressive clinical course (105). They are a selective molecular marker of secondary
GBMs and distinguish them from primary GBMs (86, 97, 101). IDH1 mutated high grade
gliomas have a more favorable prognosis than the ones without IDH1 mutation and the
sequence from more favorable to poorer outcome is: anaplastic astrocytoma (AA) with
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IDH1 mutation, GBM with IDH1mutation, AA without IDH1 mutation and GBM without
IDH1 mutation (97, 106).
G-CIMP
Analysis of the GBM DNA methylation array data generated by The Cancer Genome Atlas
Research Network (TCGA) identified G-CIMP, a DNA methylation phenotype present in
~10% of GBM (107). This phenotype is strongly associated with IDH1 mutation and
proneural tumor subtype, and is rare in primary GBM (~5–8%). There is a significant
overall survival advantage of patients with G-CIMP, proneural tumor subtype and IDH1
mutation (107–109).
EGFR
EGFR is a transmembrane tyrosine kinase on chromosome 7p12 whose downstream
signaling pathways modulate a wide range of cellular activities, including growth,
migration, and survival (110). In GBMs, EGFR signaling promotes cell division, tumor
invasiveness, and resistance to RT and chemotherapy (111–113). EGFR activity is enhanced
by upregulation of EGFR protein expression, inhibition/deletion of downstream pathway
inhibitors, constitutively active EGFR (EGFRvIII), and EGFR amplification (114, 115).
EGFR amplification results in over-expression of EGFR (116–118). Alteration of the EGFR
gene, results in over-expression of varied mutations, including the most common mutation,
EGFRvIII (variant III), as well as wild-type EGFR (EGFRwt) (119–121). EGFRvIII (variant
III) is the most common mutation among EGFR amplified GBMs and has been described in
approximately 60–70% of these tumors (120, 122). EGFRvIII over-expression was found to
be a strong predictor of poor prognosis in presence of EGFR amplification (123).
About 40% of all GBMs have EGFR amplification, and it is more common in primary as
compared to secondary GBMs (7–9, 124, 125). There is experimental evidence that EGFR
amplification may result in a less favorable prognosis; however, clinical studies are
inconclusive (72, 117, 118). Some have shown the degree of EGFR amplification to impact
survival with higher levels associated with longer median survival while others have found it
to be differentially prognostic with age (115, 126). EGFR over-expression was associated
with worse prognosis in younger patients and better prognosis in older patients (41, 72, 127).
Data also suggest existence of a complex relationship of survival in GBM with the patient’s
age, p53 and EGFR amplification. Poorer survival was noted in younger patients whose
tumors over-expressed EFGR but had normal p53 immunohistochemistry (72). Additionally,
lower levels of amplification correlated with worse response to TMZ-containing adjuvant
therapeutic regimens compared to GBMs with high amplification or none at all (126).
TP53 mutation
Mutation of the TP53 gene has been found in 60% to 70% of secondary GBMs, 25% to 30%
of primary GBMs and occurs more frequently in younger patients (9). Studies of TP53
mutations as a prognostic marker have not been definitive (72, 128, 129).
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Mutations in ATRX have been identified in multiple tumor types and appear to cause
alternative lengthening of telomeres (ALT), a presumed precursor to genomic instability
(130, 131). ATRX alterations are present mainly in tumors of an astrocytic lineage and are
specific to astrocytic tumors carrying IDH1/2 and TP53 mutations (132). They are more
common in secondary as compared to primary GBMs (132, 133).
ATRX is frequently mutated in grade II-III astrocytomas (71%), oligoastrocytomas (68%),
and secondary GBMs (57%), but is infrequent in primary (4%) and pediatric GBMs (20%)
as well as pure oligodendroglial tumors (14%) (133). ATRX mutations are associated with
alternative lengthening of telomeres phenotype among GBMs (133, 134). They cluster with
IDH1 and TP53 mutations in secondary GBMs (133).
In a prospective cohort of patients with astrocytic tumors, those harboring ATRX loss had a
significantly better prognosis than the ones that expressed ATRX and had IDH mutation
(135). Jiao et al described the prognostic molecular classification of gliomas and based on 3
gene signatures (133). The I-A signature was defined by alterations in ATRX and IDH; with
ALT and TP53 mutations. These tumors were grade II, III astrocytomas and secondary
GBMs, were often diagnosed in the fourth decade of life and had a median survival of 51
months (133). I-CF signature was defined by IDH mutations and by alterations in either
capicua transcriptional repressor (CIC), far upstream element (FUSE) binding protein 1
(FUBP1) and/or 1p/19q, rarely displayed ALT. These tumors typically had an
oligodendroglial component and were often diagnosed in the fifth decade of life with a
median survival of 96 months (133). I-X signature was defined by lack of IDH or ATRX
mutations. I-X tumors are a genetically heterogeneous group, associated with poor patient
survival 13 months, advanced patient age, and are similar to primary GBMs (133, 134).
TERT
TERT is involved in telomere maintenance which is essential for actively growing cells.
TERT mutation is one of the most frequent genetic alterations in primary adult GBMs and is
significantly higher in these tumors as compared to secondary adult or any pediatric GBMs
(73, 136). In GBMs TERT mutations are significantly correlated with EGFR amplification
but have an inverse correlation with IDH and TP53 mutations (73, 136). Although TERT
mutations have yet to be directly compared with ATRX mutations, it is highly probable that
the two are mutually exclusive. GBMs with TERT mutation have a shorter survival than
those without TERT mutations (136). However, when adjusted for GBM subtype (primary
and secondary), they do not have a significant impact on survival (136).
Genetic losses of chromosomes
Losses on chromosome 10—Some of the most frequent genetic alterations in GBMs
are genetic losses on chromosome 10 (80–90%), occurring either as loss of the entire
chromosome or as loss of only the long or short arms (9). Phosphatase and tensin (PTEN),
located at 10q23.3, was the first tumor suppressor gene identified on chromosome 10 and is
mutated in 20% to 40% of GBMs and almost exclusively in primary GBM (7, 137).
Prognostic role of 10q deletion in GBM are controversial, with some studies suggesting 10q
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loss as an indicator of poor outcome whereas others did not report a significant role as
prognostic factor (127, 129, 138, 139).
1p/19q status—1p/19q deletions (loss of the short arm of chromosome 1 and the long arm
of chromosome 19) predict response to chemotherapy and better prognosis in anaplastic
oligodendrogliomas (140). However, it has no utility in histologically unequivocal GBMs
(141).
Conclusion
While many studies have investigated the basis of incidence differences by gender, age,
race, and risk factors for GBM, many of these studies had inconclusive findings. Although
ionizing RT increases risk and allergies decrease risk, these factors do not account for a
large proportion of GBMs. Hence, further studies are warranted to untangle the complexities
of GBM etiology.
Advances have been made in development of prognostic tools and identifying molecular
markers that help predict prognosis and response to therapy. Progress in investigating the
molecular biology has led to identification of GBM subsets that are biologically similar, are
more susceptible to standard therapy and have a better prognosis. Efforts to establish the role
of IDH1 and MGMT in predicting therapeutic response is ongoing. Understanding the role
of IDH1/2 mutations in promoting gliomagenesis, its effect on prognosis, and targeting
IDH1/2 mutations in novel therapies holds promise to make advances in preventive and
treatment strategies (86).
In summary, GBM represents a molecularly heterogeneous disease with numerous sub-
classifications. The field has invested significant resources on this characterization and is
now poised to advance therapies specific to the genetic abnormalities of each subtype. The
success of m-TOR pathway inhibition for subependymal giant-cell astrocytomas and the
possibility of identifying a subtype of GBM sensitive to up-front treatment with
bevacizumab are examples, but we need much more (142, 143). The complex molecular
changes associated with GBM will likely make personalized therapy challenging and
although clinical advances in GBM are rare, we are in a new era in cancer biology. Whether
an immune based therapy or treating multiple targets will provide the breakthroughs is yet
unknown, but we expect meaningful clinical advances to occur—and soon.
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Age Adjusted Incidence Rates of Glioblastoma by Region in US, CBTRUS Statistical
Report, SEER 2006–2010. Rates are per 100,000 (2). Abbreviations: CBTRUS, Central
Brain Tumor Registry of United States.
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Age-Adjusted and Age-Specific Incidence Rates for Glioblastoma by Age at Diagnosis and
Gender, CBTRUS Statistical Report: NPCR and SEER, 2006–2010. X axis: age groups; Y
axis: incidence rates. Rates are per 100,000 and age-adjusted to the 2000 US standard
population. Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States;
NPCR, CDC's National Program of Cancer Registries; SEER, NCI's Surveillance,
Epidemiology and End Results program (2).
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3A: Average Annual Age Adjusted Incidence Rates of Glioblastoma by Race, CBTRUS
Statistical Report: NPCR and SEER, 2006–2010. X axis: race; Y axis: incidence rates.
3B: Average Annual Age Adjusted Incidence Rates of Glioblastoma by Ethnicity, CBTRUS
Statistical Report: NPCR and SEER, 2006–2010. X axis: ethnicity; Y axis: incidence rates.
Rates are per 100,000. Abbreviations: IR: Incidence Rate; AIAN, Asian Indian Alaskan
Native; API, Asian Pacific Islander; CBTRUS, Central Brain Tumor Registry of United
States; NCPR, National Program of Cancer Registries (2).
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4A: Relative Survival Rates for Glioblastoma, SEER 18 Registries, 1995–2010.
4B: Relative Survival Rates for Glioblastoma by Gender, SEER 18 registries, 1995–2010.
Number of cases in each gender: male, 16,221; female: 11,993.
4C: Relative Survival Rates for Glioblastoma by Race, SEER 18 registries, 1995–2010.
Number of cases in each race: whites, 25,360; blacks, 1,547; API, 1,151. *Relative survival
rates for American Indian/Alaskan native are excluded due to low numbers.
Thakkar et al. Page 22






















X axis: time in years; Y axis: survival in percentage. Rates are an estimate of the percentage
of patients alive at one, two, three, four, five, and ten year, respectively. Estimated by
CBTRUS using SEER Program (www.seer.cancer.gov) SEER*Stat Database: Incidence -
SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011
Sub (1973–2009 varying) - Linked To County Attributes - Total U.S., 1969–2010 Counties,
National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics
Branch, released April 2012, based on the November 2011 submission.
Abbreviation: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, CDC's
National Program of Cancer Registries; SEER, NCI's Surveillance, Epidemiology and End
Results program; API: Asian Pacific Islander (2).
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Five and Ten-Year Relative Survival Rate for Glioblastoma by Age, SEER 18 Registries,
1995–2010. X axis: age groups; Y axis: survival in percentage. Rates are in percentage (%).
Estimated by CBTRUS using SEER Program (www.seer.cancer.gov) SEER*Stat Database:
Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases,
Nov 2011 Sub (1973–2009 varying) - Linked To County Attributes - Total U.S., 1969–2010
Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer
Statistics Branch, released April 2012, based on the November 2011 submission.
Abbreviation: CBTRUS, Central Brain Tumor Registry of the United States; SEER, NCI's
Surveillance, Epidemiology and End Results program (2).
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Relationship between molecular markers and the different grades of glioma. Red = primary
glioblastoma, blue = grades II, III astrocytomas and secondary glioblastoma, purple = grades
II and III oligodendrogliomas. Abbreviations: ATRX, alpha thalassemia/mental retardation
syndrome X-linked; IDH1/2, isocitrate dehydrogenase enzyme 1/2 mutation; EGFR,
epidermal growth factor receptor, hTERT, high frequency of telomerase reverse
transcriptase (hTERT) promoter mutation.
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